TSHA - Taysha Gene Therapies, Inc.
About Taysha Gene Therapies, Inc. (https://www.tayshagtx.com)
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sean Nolan | Chief Executive Officer & Chairman | 1968 | $1,189,515 USD |
| Sukumar Nagendran | President, Head of Research & Development and Director | 1967 | $1,035,020 USD |
| Kamran Alam | Chief Financial Officer & Corporate Secretary | 1978 | $741,904 USD |
| Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program | – | – |
| Emily McGinnis | Chief Patient & External Affairs Officer | – | – |
| Frederick Porter | Chief of Staff & Technical Operations Officer | – | – |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | – | – |
| Rumana Haque-Ahmed | Chief Regulatory Officer | – | – |
| Sean McAuliffe | Chief Business Officer | – | – |
| Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | – | – |